E7107

DRUG2 trials

Sponsors

Eisai Limited, Eisai Inc.

Conditions

Cancer

Phase 1

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

SuspendedNCT00459823

Eisai LimitedCancer

Start: 2007-05-31Target: 40Updated: 2009-03-24

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

SuspendedNCT00499499

Eisai Inc.Cancer

Start: 2007-07-31End: 2010-08-31Target: 40Updated: 2009-02-04